Kidney360 . Innate Immunity and SARS-CoV-2 Vaccine Response in Hemodialysis Patients

[tetano]

Kidney360


. 2022 Aug 9;3(10):1763-1768.
doi: 10.34067/KID.0002542022. eCollection 2022 Oct 27.
Innate Immunity and SARS-CoV-2 Vaccine Response in Hemodialysis Patients


Nicolas Valentini ^{1 2} , Lorie Marchitto ^{3 4} , Maxime Raymond ¹ , Guillaume Goyette ³ , Daniel E Kaufmann ^{3 5} , Andrés Finzi ^{3 4} , Rita S Suri ^{6 7} , Caroline Lamarche ^{1 5}



Affiliations

• PMID: 36514720
• PMCID: PMC9717667
• DOI: 10.34067/KID.0002542022

Abstract

Patients receiving hemodialysis (HD) have more inflammatory monocytes and less plasmacytoid dendritic cells (DCs) compared with healthy controls.Patients on HD who have a poor antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine had fewer monocyte-derived DCs and conventional DCs compared with good responders.The defects in antigen presentation might be possible therapeutic targets to increase vaccine efficacy in HD patients.

Keywords: COVID-19; SARS-CoV-2; basic science; chronic kidney disease; dendritic cell; immune response; innate immunity; mRNA vaccine; monocyte.